BIO vs. QGEN: Bio-Rad Laboratories vs. Qiagen Stock Comparison

November 11, 2026

How do Bio-Rad Laboratories (BIO) and Qiagen (QGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO) and Qiagen (QGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Profile Item	BIO	QGEN
Name	Bio-Rad Laboratories Inc.	Qiagen N.V.
Country/Region	United States	Netherlands
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	10.26 billion USD	10.39 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	February 27, 1980	June 28, 1996
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIO

QGEN

GSPC

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Bio-Rad Laboratories (BIO) and Qiagen (QGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Bio-Rad Laboratories (BIO) and Qiagen (QGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
Total Return (1Y)	28.31%	17.09%
Total Return (3Y, Annualized)	8.52%	10.44%
Total Return (5Y, Annualized)	-11.74%	-0.72%

Risk Profile

Drawdown History

BIO

QGEN

GSPC

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Bio-Rad Laboratories (BIO) and Qiagen (QGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
Volatility (1Y, Annualized)	36.50%	35.52%
Beta (5Y)	1.03	0.56
Max Drawdown (5Y)	-72.24%	-41.97%
Avg. Volume (3M)	250.78K	3.68M

Risk-Adjusted Performance

Risk-Return Positioning

BIO and QGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
Sharpe Ratio (1Y)	0.66	0.36
Sortino Ratio (1Y)	0.98	0.60

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO) at 14.27% and Qiagen (QGEN) at 10.81% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max: 109.18%
BIO: 14.27%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.81%

Max: 109.18%
QGEN: 10.81%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO) at 39.45% and Qiagen (QGEN) at 18.20% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO: 39.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.20%

QGEN: 18.20%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Qiagen (QGEN) at 27.75% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.82%

Max: 83.12%
Q3: 14.77%
BIO: 11.82%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.75%

Max: 83.12%
QGEN: 27.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
ROE (TTM)	14.27%	10.81%
ROA (TTM)	1.50%	5.68%
Net Margin (TTM)	39.45%	18.20%
Operating Margin (TTM)	11.82%	27.75%
Gross Margin (TTM)	52.19%	67.06%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Qiagen (QGEN) reports EPS growth of 409.76%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
Revenue Growth (YoY)	0.65%	5.65%
Revenue Growth (3Y CAGR)	-2.68%	-0.81%
EPS Growth (YoY)	--	409.76%
EPS Growth (3Y CAGR)	--	-0.19%

Financial Strength

Current Ratio (MRQ)

Both Bio-Rad Laboratories (BIO) at 3.18 and Qiagen (QGEN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max: 25.13
Q3: 12.13
Median: 5.52
BIO: 3.18
Q1: 2.47
Min: 0.10

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 25.13
Q3: 12.13
Median: 5.52
QGEN: 2.63
Q1: 2.47
Min: 0.10

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Bio-Rad Laboratories (BIO) at 0.18 and Qiagen (QGEN) at 0.47 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max: 1.42
Q3: 0.65
BIO: 0.18
Median: 0.15
Q1: 0.02
Min: 0.00

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.47

Max: 1.42
Q3: 0.65
QGEN: 0.47
Median: 0.15
Q1: 0.02
Min: 0.00

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
Current Ratio (MRQ)	3.18	2.63
Debt / Equity (MRQ)	0.18	0.47
Net Debt / EBITDA	-0.73	1.08

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71%

QGEN: 0.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.21%

QGEN: 18.21%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
Dividend Yield (TTM)	0.00%	0.71%
Dividend Payout Ratio (TTM)	0.00%	18.21%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Qiagen (QGEN) at 27.21 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.14

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
BIO: 10.14
Min: 0.07

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.21

Max: 85.34
Q3: 43.46
QGEN: 27.21
Median: 26.69
Q1: 13.30
Min: 0.07

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.96

Max: 58.18
Q3: 25.77
Median: 7.30
BIO: 3.96
Q1: 3.01
Min: 0.01

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.91

Max: 58.18
Q3: 25.77
Median: 7.30
QGEN: 4.91
Q1: 3.01
Min: 0.01

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Qiagen (QGEN) at 2.99 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BIO: 1.35
Min: -5.59

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max: 13.53
Q3: 6.54
Median: 3.25
QGEN: 2.99
Q1: 1.69
Min: -5.59

Bio-Rad Laboratories (BIO) vs. Qiagen (QGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO) and Qiagen (QGEN)
Metric	BIO	QGEN
P/E Ratio (TTM)	10.14	27.21
P/S Ratio (TTM)	3.96	4.91
P/B Ratio (MRQ)	1.35	2.99
Free Cash Flow Yield (TTM)	2.65%	3.62%